Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: An 11.7T 1H-MRS study in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 51, Issue , 2014, Pages 9-15

  Perrine, Shane A ^a   Ghoddoussi, Farhad ^a   Michaels, Mark S ^a   Sheikh, Imran S ^b   McKelvey, George ^a   Galloway, Matthew P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic unpredictable stress; Gamma aminobutyric acid; Proton magnetic resonance spectroscopy

Indexed keywords

4 AMINOBUTYRIC ACID; CORTICOSTERONE; KETAMINE; ANTIDEPRESSANT AGENT; PROTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CINGULATE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BODY WEIGHT; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DEVELOPMENTAL STAGE; ENDOPHENOTYPE; EX VIVO STUDY; FORCED SWIM TEST; GABAERGIC TRANSMISSION; IMMOBILITY; MALE; NEUROCHEMISTRY; NEUROIMAGING; NEUROMODULATION; NONHUMAN; PHYSICAL STRESS; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; CINGULATE GYRUS; COMPLICATION; DIAGNOSTIC USE; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MENTAL STRESS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT; SWIMMING; TIME; TONIC IMMOBILITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAMMA-AMINOBUTYRIC ACID; GYRUS CINGULI; IMMOBILITY RESPONSE, TONIC; KETAMINE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PSYCHOLOGICAL; SWIMMING; TIME FACTORS;

EID: 84892894277     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.11.003     Document Type: Article

References (72)

1. Assis L.C., Rezin G.T., Comim C.M., Valvassori S.S., Jeremias I.C., Zugno A.I., et al. Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. Rev Bras Psiquiatr 2009, 31:247-252.
2. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
3. Banasr M., Duman R.S. Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. CNS Neurol Disord Drug Targets 2007, 6:311-320.
4. Banasr M., Duman R.S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008, 64:863-870.
5. Banasr M., Chowdhury G.M., Terwilliger R., Newton S.S., Duman R.S., Behar K.L., et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010, 15:501-511.
6. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
7. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Ashworth F., Sule A., et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 2007, 61:806-812.
8. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Boorman E., MP M., et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 2008, 11:255-260.
9. Cotter D., Mackay D., Landau S., Kerwin R., Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001, 58:545-553.
10. Cox B.M., Alsawah F., McNeill P.C., Galloway M.P., Perrine S.A. Neurochemical, hormonal, and behavioral effects of chronic unpredictable stress in the rat. Behav Brain Res 2011, 220:106-111.
11. Doyle J.R., Yamamoto B.K. Serotonin 2 receptor modulation of hyperthermia, corticosterone, and hippocampal serotonin depletions following serial exposure to chronic stress and methamphetamine. Psychoneuroendocrinology 2010, 35:629-633.
12. Drevets W.C., Savitz J., Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 2008, 13:663-681.
13. Duman R.S., Li N., Liu R.J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62:35-41.
14. Garcia L.S., Comim C.M., Valvassori S.S., Reus G.Z., Andreazza A.C., Stertz L., et al. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol 2008, 103:502-506.
15. Garcia L.S., Comim C.M., Valvassori S.S., Reus G.Z., Barbosa L.M., Andreazza A.C., et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:140-144.
16. Garcia L.S., Comim C.M., Valvassori S.S., Reus G.Z., Stertz L., Kapczinski F., et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:450-455.
17. Garcia-Garcia A.L., Elizalde N., Matrov D., Harro J., Wojcik S.M., Venzala E., et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol Psychiatry 2009, 66:275-282.
18. Ghasemi M., Raza M., Dehpour A.R. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J Psychopharmacol 2010, 24:585-594.
19. Ghoddoussi F., Galloway M.P., Jambekar A., Bame M., Needleman R., Brusilow W.S. Methionine sulfoximine, an inhibitor of glutamine synthetase, lowers brain glutamine and glutamate in a mouse model of ALS. J Neurol Sci 2010, 290:41-47.
20. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2010, 11:33-36.
21. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007, 64:193-200.
22. Hemanth Kumar B.S., Mishra S.K., Rana P., Singh S., Khushu S. Neurodegenerative evidences during early onset of depression in CMS rats as detected by proton magnetic resonance spectroscopy at 7T. Behav Brain Res 2012, 232:53-59.
23. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007, 27:11496-11500.
24. 1H MR spectroscopy. J Neurosci Methods 2007, 165:89-94.
25. Hong S.T., Choi C.B., Park C., Moon H.Y., Hong K.S., Cheong C., et al. Specific hippocampal choline decrease in an animal model of depression. Br J Radiol 2009, 82:549-553.
26. Institute of Laboratory Animal Resources (U.S.) Guide for the care and use of laboratory animals 1996, National Academy Press, Washington, D.C. 7th ed.
27. Johnson B.N., Yamamoto B.K. Chronic unpredictable stress augments +3,4-methylenedioxymethamphetamine-induced monoamine depletions: the role of corticosterone. Neuroscience 2009, 159:1233-1243.
28. Kessler R.C., Angermeyer M., Anthony J.C., DEG R., Demyttenaere K., Gasquet I., et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007, 6:168-176.
29. Knox D., Perrine S.A., George S.A., Galloway M.P., Liberzon I. Single prolonged stress decreases glutamate, glutamine, and creatine concentrations in the rat medial prefrontal cortex. Neurosci Lett 2010, 480:16-20.
30. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011, 224:107-111.
31. Krystal J.H. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly 2007, 137:215-216.
32. 1H magnetic resonance spectroscopy. Neurochem Res 2008, 33:2342-2349.
33. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
34. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011, 69:754-761.
35. Ma X.C., Dang Y.H., Jia M., Ma R., Wang F., Wu J., et al. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PloS One 2013, 8:e56053.
36. Machado-Vieira R., Yuan P., Brutsche N., DiazGranados N., Luckenbaugh D., Manji H.K., et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 2009, 70:1662-1666.
37. Maeng S., Zarate C.A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007, 9:467-474.
38. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
39. Mathew S.J., Keegan K., Smith L. Glutamate modulators as novel interventions for mood disorders. Rev Bras Psiquiatr 2005, 27:243-248.
40. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33:2080-2092.
41. Monteggia L.M., Gideons E., Kavalali E.T. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 2012, 73(12):1199-1203.
42. O'Leary-Moore S.K., Galloway M.P., McMechan A.P., Hannigan J.H., Bowen S.E. Region-dependent alterations in glutamate and GABA measured by high-resolution magnetic resonance spectroscopy following acute binge inhalation of toluene in juvenile rats. Neurotoxicol Teratol 2007, 29:466-475.
43. Ongur D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998, 95:13290-13295.
44. Ortiz J., Fitzgerald L.W., Lane S., Terwilliger R., Nestler E.J. Biochemical adaptations in the mesolimbic dopamine system in response to repeated stress. Neuropsychopharmacology 1996, 14:443-452.
45. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Elsevier, Boston. 6th ed.
46. Perrine S.A., Sheikh I.S., Nwaneshiudu C.A., Schroeder J.A., Unterwald E.M. Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat. Neuropharmacology 2008, 54:355-364.
47. 1H-magnetic resonance spectroscopy in the rat. NMR Biomed 2009, 22:419-425.
48. Perrine S.A., Ghoddoussi F., Michaels M.S., Hyde E.M., Kuhn D.M., Galloway M.P. MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain. Neurotoxicology 2010, 31:654-661.
49. Perrine S.A., O'Leary-Moore S.K., Galloway M.P., Hannigan J.H., Bowen S.E. Binge toluene exposure alters glutamate, glutamine and GABA in the adolescent rat brain as measured by proton magnetic resonance spectroscopy. Drug Alcohol Depend 2011, 115:101-106.
50. Pilc A., Wieronska J.M., Skolnick P. Glutamate-based antidepressants: preclinical psychopharmacology. Biol Psychiatry 2013, 73(12):1125-1132.
51. Popik P., Kos T., Sowa-Kucma M., Nowak G. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) 2008, 198:421-430.
52. Price R.B., Shungu D.C., Mao X., Nestadt P., Kelly C., Collins K.A., et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 2009, 65:792-800.
53. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993, 30:672-679.
54. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
55. Rezin G.T., Goncalves C.L., Daufenbach J.F., Fraga D.B., Santos P.M., Ferreira G.K., et al. Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress. Brain Res Bull 2009, 79:418-421.
56. Salvadore G., van der Veen J.W., Zhang Y., Marenco S., Machado-Vieira R., Baumann J., et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol 2012, 15:1063-1072.
57. Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999, 56:1043-1047.
58. Sanacora G., Mason G.F., Rothman D.L., Krystal J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002, 159:663-665.
59. Sanacora G., Mason G.F., Rothman D.L., Hyder F., Ciarcia J.J., Ostroff R.B., et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 2003, 160:577-579.
60. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004, 61:705-713.
61. Sanacora G., Fenton L.R., Fasula M.K., Rothman D.L., Levin Y., Krystal J.H., et al. Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biol Psychiatry 2006, 59:284-286.
62. Sartorius A., Mahlstedt M.M., Vollmayr B., Henn F.A., Ende G. Elevated spectroscopic glutamate/gamma-amino butyric acid in rats bred for learned helplessness. Neuroreport 2007, 18:1469-1473.
63. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20years on. Trends Pharmacol Sci 2009, 30:563-569.
64. Sofia R.D., Harakal J.J. Evaluation of ketamine HCl for anti-depressant activity. Arch Int Pharmacodyn Ther 1975, 214:68-74.
65. Valentine G.W., Mason G.F., Gomez R., Fasula M., Watzl J., Pittman B., et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 2011, 191:122-127.
66. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997, 134:319-329.
67. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.
68. Willner P., Muscat R., Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992, 16:525-534.
69. Yang J., Shen J. In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. Neuroscience 2005, 135:927-937.
70. 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 2006, 147:1-25.
71. Yilmaz A., Schulz D., Aksoy A., Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002, 71:341-344.
72. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.